SECURITIESANDEXCHANGECOMMISSION
Washington, D.C. 20549
_______________________________
FORM8-K
CURRENT REPORT
|
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
__________________________________
Date of report (Date of earliest event reported):August 6, 2004 (August 5, 2004)
DOV Pharmaceutical, Inc.
__________________________________________________________________________
(Exact name of registrant as specified in charter)
|
| Delaware | 000-49730 | 22-3374365 |
|
|
|
| (State or other jurisdiction | (Commission file number) | (IRS employer |
| of incorporation) | | identification no.) |
433 Hackensack Avenue, Hackensack, NJ 07601
(Address of principal executive offices) (Zip code)
(201) 968-0980
(Registrant’s telephone number, including area code)
Item 5. Other Events and Required FD Disclosure.
On August 5, 2004, registrant issued a press release, a copy of which is included as an exhibit to this filing.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits. The following exhibit is furnished herewith:
| Exhibit | |
| Number | Title |
| |
| 99.1 | Press release dated August 5, 2004, issued by registrant |
Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | DOV Pharmaceutical, Inc. |
| |
| |
| Date: August 6, 2004 | /s/ Arnold Lippa |
| |
|
| | Arnold Lippa |
| | Chief Executive Officer |
EXHIBIT INDEX
| Exhibit | |
| Number | Title |
| |
| 99.1 | Press release dated August 5, 2004, issued by registrant |
